Dynamic regulation of hypothalamic neuropeptide gene expression and food intake by melanocortin analogues and reversal with melanocortin-4 receptor antagonist.

Kim RY, Shin SW, Kim BJ, Lee W, Baik JH

Biochemical and biophysical research communications1 Apr 2005Cited by 9 (Europe PMC)

PMID15766551DOI10.1016/j.bbrc.2005.02.105PepBankPUB-15766551

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

01AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Efficacy outcome
In mice, pooled intracerebroventricular alpha-MSH analogues, including NDP-MSH, significantly inhibited food intake compared with saline control.
In plain wordsIn mice, a group of alpha-MSH analogues that includes NDP-MSH reduced food intake compared with saline.
Peptide
Melanotan I (afamelanotide)
Outcome
DecreaseFood intake (time course)
Study
mousen: not reported in source
Comparator
Saline
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
resulted in a significant inhibition of both time course food intake and body weight gain, compared to the saline-administered control.
1 context sentence(design, population, supporting numbers)
Summary · context
Acute and chronic intracerebroventricular administration of several different analogues of alpha-MSH, such as alpha-MSH, NDP-MSH, alpha-MSH-ND, [Gln(6)]alpha-MSH-ND, and [Lys(6)]alpha-MSH-ND, which were substituted in the position of His(6) with Gln and Lys, and cyclic16k-MSH
In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).
Report a problemFND-1576655101
02AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Efficacy outcome
In mice, pooled intracerebroventricular alpha-MSH analogues, including NDP-MSH, significantly inhibited body weight gain compared with saline control.
In plain wordsIn mice, a group of alpha-MSH analogues that includes NDP-MSH reduced body weight gain compared with saline.
Peptide
Melanotan I (afamelanotide)
Outcome
DecreaseBody weight gain
Study
mousen: not reported in source
Comparator
Saline
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
resulted in a significant inhibition of both time course food intake and body weight gain, compared to the saline-administered control.
1 context sentence(design, population, supporting numbers)
Summary · context
Acute and chronic intracerebroventricular administration of several different analogues of alpha-MSH, such as alpha-MSH, NDP-MSH, alpha-MSH-ND, [Gln(6)]alpha-MSH-ND, and [Lys(6)]alpha-MSH-ND, which were substituted in the position of His(6) with Gln and Lys, and cyclic16k-MSH
In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).
Report a problemFND-1576655102

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.